Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | ESRRG | P62508 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30585005 | 0.87 | HDAC6 (0.52) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL25400357 | 0.87 | IDH1 (0.44) | PTGER4CACNA1GCACNA1HCACNA1IIDH1 | |
| SCHEMBL30585001 | 0.87 | HDAC6 (0.52) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL6840365 | 0.84 | KDM5A (0.47) | PTGER4HSD17B10HDAC6HDAC1 | |
| SCHEMBL25403703 | 0.81 | THRB (0.54) | PTGER4HSD17B10RXRARXRBCACNA1G | |
| SCHEMBL30585047 | 0.81 | THRB (0.54) | PTGER4HSD17B10RXRARXRBCACNA1G | |
| SCHEMBL30585029 | 0.81 | PTGER4 (0.46) | PTGER4IDH1HDAC6HDAC1 | |
| SCHEMBL25401918 | 0.78 | KDM4E (0.47) | PTGER4HSD17B10RXRAKMT2AMRGPRX4 | |
| SCHEMBL29241303 | 0.77 | KMT2A (0.50) | SMN1; SMN2HSD17B10POLBMEN1KMT2A | |
| SCHEMBL25402055 | 0.77 | HDAC6 (0.59) | SMN1; SMN2PTGER4HSD17B10CACNA1GCACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197369-A1 | NOVEL HETEROCYCLIC INHIBITOR FOR HISTONE DEACETYLASE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SOOKMYUNG WOMEN'S UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2025-06-19 | — | — | US | disclosed |
| EP-4494640-A1 | NOVEL HETEROCYCLIC INHIBITOR FOR HISTONE DEACETYLASE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Sookmyung Women's University Industry-Academic Cooperation Foundation (KR) | 2025-01-22 | — | — | EP | disclosed |
| CN-119212701-A | Novel histone deacetylase heterocycle inhibitor and pharmaceutical composition containing the same | 淑明女子大学校 产学协力团 | 2024-12-27 | — | — | CN | disclosed |
| WO-2023177250-A1 | NOVEL HETEROCYCLIC INHIBITOR FOR HISTONE DEACETYLASE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 숙명여자대학교산학협력단 | 2023-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197369-A1 | NOVEL HETEROCYCLIC INHIBITOR FOR HISTONE DEACETYLASE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | HDAC1, HDAC6, HDAC5 | SMN1; SMN2 1839/4885PTGER4 3788/4885HSD17B10 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.